Volume 1 Supplement 1

Abstracts of the 28th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)

Open Access

Expression of cancer testis antigens and its correlation with clinicopathological parameters in hepatocellular carcinoma

  • Meng Wang1, 2,
  • Xin-feng Chen2, 6,
  • Zhi-qin Li3,
  • Zhen Zhang2, 6,
  • Dong-li Yue2, 6,
  • Yan-hong Liu1,
  • Dong Jiang1,
  • Yu-ling Sun4,
  • Yong-fu Zhao4,
  • Shu-huan Wu3,
  • Jian-sheng Li1 and
  • Yi Zhang2, 5, 6
Journal for ImmunoTherapy of Cancer20131(Suppl 1):P250

DOI: 10.1186/2051-1426-1-S1-P250

Published: 7 November 2013

Background

Many therapies such as surgery, chemical or physical approaches have been used for treatment of HCC; however, the outcome is still poor. Cancer immunotherapy is considered to be one of the promising strategies in recent years.

Methods

Expression of CTAs genes including MAGE A3, MAGE A4, MAGE C2 and NY-ESO-1 genes was detected with reverse transcription polymerase chain reaction (RT-PCR) in HCC tissues and corresponding adjacent non-cancerous tissues from 71 HCC patients.

Results

87.3% of HCC tumor tissue samples expressed at least 1 CTAs. HCC adjacent non-cancerous tissues did not express CTAs. 78.9% tumor tissue samples expressed MAGE-A3 mRNA, 33.8% samples expressed MAGE-A4 mRNA, 74.6% samples expressed MAGE-C2 mRNA and 14.1% samples expressed NY-ESO-1 mRNA. The expression of CTAs showed correlation with Ki67(r=0.27, P=0.02) and tumor stages (r=0.31, P=0.01), no correlation with clinical parameters such as age, gender, ALT, HLA-A2 positive, CA125, CA199, HBV or HCV infection and tumor size (P>0.05). The expression of MAGE-A3 showed correlation with the high expressions of CEA in serum (r=0.30, P=0.03), AFP in serum (r=0.26, P=0.03) and lymph node metastases (r=0.30, P=0.01).

Conclusion

Our findings demonstrate the cancer testis expression of CTAs genes show correlations with tumor stages and proliferation and may represent useful targets for tumor specific immunotherapy in HCC patients.
Table 1

Clinicopathological characteristics of the HCC patients

Characteristics

No.patients

%

Gender

71

 

Male

54

76.1

Female

17

23.9

Age(y)

  

<55

47

66.2

≥55

24

33.8

ALT(IU/ml)

  

<80

61

85.9

≥80

10

14.1

HLA A2

  

Positive

41

57.7

Negative

30

42.3

AFP(ng/ml)

  

≤10

30

42.3

>10

41

57.7

Tumor size(cm)

  

≤5

43

60.6

>5

28

39.4

TNM classification

  

I or II

34

47.9

III or IV

37

52.1

Etiology

  

HBV

45

63.4

HCV

6

8.5

No

20

28.1

Ki67(%)

  

≤40

30

42.3

>40

41

57.7

CTAs

  

Positive

62

87.3

Negative

9

12.7

Average age(year)

53.7±11.5

 

Authors’ Affiliations

(1)
Department of Gastroenterology, the First Affiliated Hospital of Zhengzhou University
(2)
Biotherapy Center, the First Affiliated Hospital of Zhengzhou University
(3)
Department of Infectious Diseases, the First Affiliated Hospital of Zhengzhou University
(4)
Department of Hepatobiliary Surgery, the First Affiliated Hospital of Zhengzhou University
(5)
Department of Bioengineering, the First Affiliated Hospital of Zhengzhou University
(6)
Department of Oncology, the First Affiliated Hospital of Zhengzhou University

Copyright

© Wang et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement